JP2007513089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513089A5 JP2007513089A5 JP2006541234A JP2006541234A JP2007513089A5 JP 2007513089 A5 JP2007513089 A5 JP 2007513089A5 JP 2006541234 A JP2006541234 A JP 2006541234A JP 2006541234 A JP2006541234 A JP 2006541234A JP 2007513089 A5 JP2007513089 A5 JP 2007513089A5
- Authority
- JP
- Japan
- Prior art keywords
- nme
- ethyl
- nhso
- nhch
- nhs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-methyl-3-hydroxypentyl Chemical group 0.000 claims 61
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 11
- 239000000651 prodrug Chemical class 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 4
- 102000009310 vitamin D receptors Human genes 0.000 claims 4
- 108050000156 vitamin D receptors Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 241000219198 Brassica Species 0.000 claims 2
- 235000003351 Brassica cretica Nutrition 0.000 claims 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 235000010460 mustard Nutrition 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000004927 skin cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010034944 Photokeratitis Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000002113 chemopreventative effect Effects 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 231100000255 pathogenic effect Toxicity 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- MANBPTLOBKIRJW-UHFFFAOYSA-N CCC(C)(c1ccc(C(NC(C)C(O)=O)=O)c(C)c1)c(cc1C)ccc1OCC(CC)(CC)O Chemical compound CCC(C)(c1ccc(C(NC(C)C(O)=O)=O)c(C)c1)c(cc1C)ccc1OCC(CC)(CC)O MANBPTLOBKIRJW-UHFFFAOYSA-N 0.000 description 1
- PAXMWKVXJARZBA-ISLYRVAYSA-N CCC(CC)(/C=C/c1c(C)cc(C(CC)(CC)c(cc2)cc(C)c2C(N(C)C(C)C(O)=O)=O)cc1)O Chemical compound CCC(CC)(/C=C/c1c(C)cc(C(CC)(CC)c(cc2)cc(C)c2C(N(C)C(C)C(O)=O)=O)cc1)O PAXMWKVXJARZBA-ISLYRVAYSA-N 0.000 description 1
- IDRUIAKSBRFWPC-UHFFFAOYSA-N CCC(CC)(C(C)C(c1ccc(C(CC)(CC)c2ccc(C(N(C)C(C)C(O)=O)=O)c(C)c2)cc1C)=O)O Chemical compound CCC(CC)(C(C)C(c1ccc(C(CC)(CC)c2ccc(C(N(C)C(C)C(O)=O)=O)c(C)c2)cc1C)=O)O IDRUIAKSBRFWPC-UHFFFAOYSA-N 0.000 description 1
- WYRJFBABNZKXSM-UHFFFAOYSA-N CCC(CC)(C(C)Cc1ccc(C(CC)(CC)c2ccc(C(NCC(O)=O)=O)c(C)c2)cc1C)O Chemical compound CCC(CC)(C(C)Cc1ccc(C(CC)(CC)c2ccc(C(NCC(O)=O)=O)c(C)c2)cc1C)O WYRJFBABNZKXSM-UHFFFAOYSA-N 0.000 description 1
- DQLDOVCZTMJGEY-UHFFFAOYSA-N CCC(CC)(CC(c1c(C)cc(C(CC)(CC)c2ccc(C(N(C)C(C)C(O)=O)=O)c(C)c2)cc1)=O)O Chemical compound CCC(CC)(CC(c1c(C)cc(C(CC)(CC)c2ccc(C(N(C)C(C)C(O)=O)=O)c(C)c2)cc1)=O)O DQLDOVCZTMJGEY-UHFFFAOYSA-N 0.000 description 1
- QEQTXTIBPIPBPB-UHFFFAOYSA-N CCC(CC)(CC(c1ccc(C(CC)(CC)c2ccc(C(N(C)CC(O)=O)=O)c(C)c2)cc1C)=O)O Chemical compound CCC(CC)(CC(c1ccc(C(CC)(CC)c2ccc(C(N(C)CC(O)=O)=O)c(C)c2)cc1C)=O)O QEQTXTIBPIPBPB-UHFFFAOYSA-N 0.000 description 1
- 0 CCC(CC)(COc1c(C)cc(C(CC)(CC)c2ccc(C(NCI*)=O)c(C)c2)cc1)O Chemical compound CCC(CC)(COc1c(C)cc(C(CC)(CC)c2ccc(C(NCI*)=O)c(C)c2)cc1)O 0.000 description 1
- QGUUJOKCIVSNLN-UHFFFAOYSA-N CCC(CC)(COc1ccc(C(CC)(CC)c2ccc(C(NC(C)(C)C(O)=O)=O)c(C)c2)cc1C)O Chemical compound CCC(CC)(COc1ccc(C(CC)(CC)c2ccc(C(NC(C)(C)C(O)=O)=O)c(C)c2)cc1C)O QGUUJOKCIVSNLN-UHFFFAOYSA-N 0.000 description 1
- KYSWXGWXVINUGS-UHFFFAOYSA-N CCC(CC)(COc1ccc(C(CC)(CC)c2ccc(C(NCC(O)=O)=O)c(C)c2)cc1C)O Chemical compound CCC(CC)(COc1ccc(C(CC)(CC)c2ccc(C(NCC(O)=O)=O)c(C)c2)cc1C)O KYSWXGWXVINUGS-UHFFFAOYSA-N 0.000 description 1
- ZPRATJBAXOLWRD-SAPNQHFASA-N CCC(CC)(c1cc(C)c(/C=C/C2(CCCCC2)O)cc1)c1ccc(C(NCC(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1cc(C)c(/C=C/C2(CCCCC2)O)cc1)c1ccc(C(NCC(O)=O)=O)c(C)c1 ZPRATJBAXOLWRD-SAPNQHFASA-N 0.000 description 1
- GYMOULFBJRNUQM-UHFFFAOYSA-N CCC(CC)(c1cc(C)c(CC(C2(CCCC2)O)=C)cc1)c(cc1)cc(C)c1C(N(C)CC(O)=O)=O Chemical compound CCC(CC)(c1cc(C)c(CC(C2(CCCC2)O)=C)cc1)c(cc1)cc(C)c1C(N(C)CC(O)=O)=O GYMOULFBJRNUQM-UHFFFAOYSA-N 0.000 description 1
- BUCSEODDSPQTQI-OBGWFSINSA-N CCC(CC)(c1ccc(/C=C/C2(CCCCC2)O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(/C=C/C2(CCCCC2)O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 BUCSEODDSPQTQI-OBGWFSINSA-N 0.000 description 1
- VDVDGQGTZJNFOS-UHFFFAOYSA-N CCC(CC)(c1ccc(C(C(C)C2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)C(C)(C)C(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(C(C(C)C2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)C(C)(C)C(O)=O)=O)c(C)c1 VDVDGQGTZJNFOS-UHFFFAOYSA-N 0.000 description 1
- VQIJVPPZBVHILA-UHFFFAOYSA-N CCC(CC)(c1ccc(C(C(C)C2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)C(C)C(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(C(C(C)C2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)C(C)C(O)=O)=O)c(C)c1 VQIJVPPZBVHILA-UHFFFAOYSA-N 0.000 description 1
- CFYVEHIBIWASNH-UHFFFAOYSA-N CCC(CC)(c1ccc(C(C(C)C2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(C(C(C)C2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 CFYVEHIBIWASNH-UHFFFAOYSA-N 0.000 description 1
- SWBUNTNTZSPXGT-UHFFFAOYSA-N CCC(CC)(c1ccc(C(CC2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(C(CC2(CCCC2)O)=O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 SWBUNTNTZSPXGT-UHFFFAOYSA-N 0.000 description 1
- UXJRTPKQBKQFEL-UHFFFAOYSA-N CCC(CC)(c1ccc(C(N(C)CC(O)=O)=O)c(C)c1)c(cc1)cc(C)c1OC(C)C1(CCCC1)O Chemical compound CCC(CC)(c1ccc(C(N(C)CC(O)=O)=O)c(C)c1)c(cc1)cc(C)c1OC(C)C1(CCCC1)O UXJRTPKQBKQFEL-UHFFFAOYSA-N 0.000 description 1
- STFINMYYWBPHAO-UHFFFAOYSA-N CCC(CC)(c1ccc(CC(C)C2(CCCC2)O)c(C)c1)c1ccc(C(NCC(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(CC(C)C2(CCCC2)O)c(C)c1)c1ccc(C(NCC(O)=O)=O)c(C)c1 STFINMYYWBPHAO-UHFFFAOYSA-N 0.000 description 1
- SDCPZCMWYKLDPB-UHFFFAOYSA-N CCC(CC)(c1ccc(CCC2(CCCC2)O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 Chemical compound CCC(CC)(c1ccc(CCC2(CCCC2)O)c(C)c1)c1ccc(C(N(C)CC(O)=O)=O)c(C)c1 SDCPZCMWYKLDPB-UHFFFAOYSA-N 0.000 description 1
- HUTNXAYRNHOZHL-UHFFFAOYSA-N Cc1c[o]c(O)n1 Chemical compound Cc1c[o]c(O)n1 HUTNXAYRNHOZHL-UHFFFAOYSA-N 0.000 description 1
- ZMEVDFFLOPFGCR-UHFFFAOYSA-N Cc1c[s]c(O)n1 Chemical compound Cc1c[s]c(O)n1 ZMEVDFFLOPFGCR-UHFFFAOYSA-N 0.000 description 1
- DXPMELADVQYNOJ-UHFFFAOYSA-N Cc1c[s]nc1O Chemical compound Cc1c[s]nc1O DXPMELADVQYNOJ-UHFFFAOYSA-N 0.000 description 1
- ICMJQBNCXFJBPE-UHFFFAOYSA-N Cc1cnc(O)[s]1 Chemical compound Cc1cnc(O)[s]1 ICMJQBNCXFJBPE-UHFFFAOYSA-N 0.000 description 1
- HOPFEDLIYBPKII-UHFFFAOYSA-N OC1=NSNC1 Chemical compound OC1=NSNC1 HOPFEDLIYBPKII-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52330103P | 2003-11-20 | 2003-11-20 | |
| PCT/US2004/037182 WO2005051893A2 (en) | 2003-11-20 | 2004-11-16 | Vitamin d receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513089A JP2007513089A (ja) | 2007-05-24 |
| JP2007513089A5 true JP2007513089A5 (https=) | 2007-12-13 |
| JP4589337B2 JP4589337B2 (ja) | 2010-12-01 |
Family
ID=34632767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541234A Expired - Fee Related JP4589337B2 (ja) | 2003-11-20 | 2004-11-16 | ビタミン受容体調節剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7595345B2 (https=) |
| EP (1) | EP1687258A2 (https=) |
| JP (1) | JP4589337B2 (https=) |
| CA (1) | CA2544501A1 (https=) |
| WO (1) | WO2005051893A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| DK1836151T3 (da) | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
| CA2589667A1 (en) | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| TW200716536A (en) * | 2005-06-09 | 2007-05-01 | Chugai Pharmaceutical Co Ltd | Vitamin D compounds |
| CA2622322A1 (en) * | 2005-09-16 | 2007-03-22 | Selamine Ltd | Bisphosphonate formulation |
| HUE034458T2 (en) | 2008-07-02 | 2018-02-28 | British Columbia Cancer Agency Branch | Diglycidyl ether derivatives, therapeutics and methods for their use |
| DK3988541T3 (da) | 2015-01-13 | 2024-09-16 | British Columbia Cancer Agency Branch | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse |
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| CN115916170A (zh) | 2020-04-17 | 2023-04-04 | 埃萨制药股份有限公司 | 固体形式的n-末端结构域雄激素受体抑制剂及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US135484A (en) * | 1873-02-04 | Edward manuel | ||
| US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
| FR2738745B1 (fr) * | 1995-09-15 | 1997-10-24 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations |
| CA2214929A1 (en) * | 1996-09-26 | 1998-03-26 | Charles Willis Lugar, Iii | Naphthofluorene compounds, intermediates, compositions and methods |
| US6218430B1 (en) | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) * | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| WO2004063348A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
| EP1587906A2 (en) * | 2003-01-10 | 2005-10-26 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| CA2589667A1 (en) | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
-
2004
- 2004-11-16 US US10/579,562 patent/US7595345B2/en not_active Expired - Fee Related
- 2004-11-16 EP EP04800873A patent/EP1687258A2/en not_active Withdrawn
- 2004-11-16 CA CA002544501A patent/CA2544501A1/en not_active Abandoned
- 2004-11-16 WO PCT/US2004/037182 patent/WO2005051893A2/en not_active Ceased
- 2004-11-16 JP JP2006541234A patent/JP4589337B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513089A5 (https=) | ||
| RU2012140454A (ru) | Способ синтеза соединений диарилтиогидантоина и диарилгидантоина | |
| ES2276062T3 (es) | Metodo para sintetizar 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol. | |
| JP2011526250A5 (https=) | ||
| CA2544501A1 (en) | Vitamin d receptor modulators | |
| CA2546729A1 (en) | Phenyl-furan compounds as vitamin d receptor modulators | |
| LT3983B (en) | Novel vitamin d analogues, process for their preparation, intermediate chemical compounds and pharmaceutical compositions | |
| EP2951152B1 (en) | (22e)-2-methylene-22-dehydro-1 ,24,25-trihydroxy-19-nor-vitamin d3 analogs | |
| JP2007512326A5 (https=) | ||
| ES2387714T3 (es) | Análogos de 2-metilen-20-metil-19,24,25,26,27-pentanor-vitamina D | |
| CA2544517A1 (en) | Vitamin d receptor modulators | |
| CA2506891A1 (en) | Vitamin d receptor modulators | |
| JP4803939B2 (ja) | ビタミンｄ誘導体 | |
| JP2007512327A5 (https=) | ||
| AU2005309805B2 (en) | 17,20(Z)-dehydro vitamin D analogs and their uses | |
| NZ563758A (en) | 19,26,27-Trinor-1alpha,25-dihydroxyvitamin D3 compounds | |
| CA2837882C (en) | (22e)-2-methylene-26,27-cyclo-22-dehydro-1.alpha.-hydroxy-19-norvitamin d3 derivatives | |
| CN107098799B (zh) | 一种活性维生素d3类药物cd环中间体的制备方法 | |
| Thomas et al. | Synthesis and preliminary biological evaluation of new antiproliferative aromatic analogues of 1α, 25-dihydroxyvitamin D3 | |
| AU2009268567B2 (en) | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs | |
| US7504530B2 (en) | Methods for the preparation of fispemifene from ospemifene | |
| CA2603328A1 (en) | 2-methylene-19-nor-(23s)-25-dehydro-1.alpha.-hydroxyvitamin d3-26,23-lactone and 2-methylene-19-nor-(23r)-25-dehydro-1.alpha.-hydroxyvitamin d3-26,23-lactone | |
| CN110740995B (zh) | 制备取代苯氧基苯基醇的方法 | |
| CA2597568A1 (en) | 2-methylene-19-nor-(20s-24epi)-1.alpha.,25-dihydroxyvitamin-d2 | |
| AU2009268508A1 (en) | 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs |